<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="ba74e3cd-b06f-4145-b284-5fd6b84ff3c9"><labelDrug name="Pradaxa"><Normalization><mmtx cui="C2940579" preferredWord="Pradaxa" semType="phsu"/></Normalization></labelDrug><generic name="dabigatran etexilate mesylate"/><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1" text="PRADAXA (dabigatran etexilate mesylate) capsule" type="negative"><entity charOffset="9:38" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.0" text="dabigatran etexilate mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C2343849" phraseText="(dabigatran etexilate mesylate" preferredWord="Dabigatran etexilate Mesylate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.1" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.1.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2" text="The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is  -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate." type="negative"><entity charOffset="22:51" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.0" text="dabigatran etexilate mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C2343849" phraseText="The chemical name for dabigatran etexilate mesylate," preferredWord="Dabigatran etexilate Mesylate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="55:80" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.1" text="direct thrombin inhibitor" type="Biomedical_Entity"><Normalization><mmtx cui="C0003440" phraseText="a direct thrombin inhibitor," preferredWord="Antithrombins" semType="bacs, phsu, aapp"/><RxNorm RxCui="3525"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.2.e.1"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11" text="If PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant [see Dosage and Administration (2.6)]." type="negative"><entity charOffset="3:10" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.0" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="110:123" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.1" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="coverage with another anticoagulant" preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.11.e.1"/></sentence><sentence biomedicalEntities="5" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16" lineNumber="23" text="Risk factors for bleeding include the concomitant use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). " type="irregular"><entity charOffset="63:103" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.0" text="drugs that increase the risk of bleeding" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="the concomitant use of other drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="17:25" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.1" text="bleeding" type="Specific_Interaction"/><entity charOffset="111:131" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.3" text="anti-platelet agents" type="Drug_Class"><Normalization><mmtx cui="C0040616" phraseText="anti-platelet agents," preferredWord="Anti-Anxiety Agents" semType="phsu"/><RxNorm RxCui="113928"/></Normalization></entity><entity charOffset="133:140" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.4" text="heparin" type="Drug"><Normalization><mmtx cui="C0019134" phraseText="heparin," preferredWord="Heparin" semType="bacs, phsu, carb"/><mmtx cui="C0770546" phraseText="heparin," preferredWord="heparin, porcine" semType="bacs, phsu, carb"/><RxNorm RxCui="5224"/></Normalization></entity><entity charOffset="142:154" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.5" text="fibrinolytic" type="Drug_Class"><Normalization><RxNorm RxCui="934"/></Normalization></entity><entity charOffset="183:189" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.6" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="chronic use of NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><classClassMembership drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.3"/><drugClassMembership drug="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.4" drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.0"/><classClassMembership drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.5"/><classClassMembership drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.6"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.0"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.15" text="Discontinue PRADAXA in patients with active pathological bleeding [see Dosage and Administration (2.2)]."><entity charOffset="12:19" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.15.e.0" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="PRADAXA in patients" preferredWord="Pradaxa" semType="phsu"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.16.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17" text="PRADAXA s anticoagulant activity and half-life are increased in patients with renal impairment [see Clinical Pharmacology (12.2)]." type="negative"><entity charOffset="10:23" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.0" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C0003280" phraseText="PRADAXA s anticoagulant activity" preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.1" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="PRADAXA s anticoagulant activity" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.17.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21" text="Activated prothrombin complex concentrates (aPCCs, e.g., FEIBA), or recombinant Factor VIIa, or concentrates of coagulation factors II, IX or X may be considered but their use has not been evaluated in clinical trials. " type="negative"><entity charOffset="57:62" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0" text="feiba" type="Biomedical_Entity"><Normalization><mmtx cui="C0082559" phraseText="FEIBA" preferredWord="Feiba" semType="phsu, aapp"/><RxNorm RxCui="968897"/></Normalization></entity><entity charOffset="136:138" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1" text="ix" type="Biomedical_Entity"><Normalization><mmtx cui="C0015491" phraseText="IX" preferredWord="Factor IX" semType="bacs, phsu, aapp"/><RxNorm RxCui="4249"/></Normalization></entity><entity charOffset="68:91" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2" text="recombinant factor viia" type="Biomedical_Entity"><Normalization><mmtx cui="C0534191" phraseText="recombinant Factor VIIa," preferredWord="recombinant FVIIa" semType="phsu, aapp"/><RxNorm RxCui="8410"/></Normalization></entity><entity charOffset="0:42" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3" text="activated prothrombin complex concentrates" type="Biomedical_Entity"><Normalization><mmtx cui="C0358606" phraseText="Activated prothrombin complex concentrates" preferredWord="Factor VIII by-passing fraction products" semType="phsu"/><RxNorm RxCui="751543"/></Normalization></entity><entity charOffset="112:134" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4" text="coagulation factors ii" type="Biomedical_Entity"><Normalization><mmtx cui="C0033706" phraseText="concentrates of coagulation factors II," preferredWord="Prothrombin" semType="bacs, phsu, aapp"/><RxNorm RxCui="1637"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.21.e.4"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22" text="Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. " type="negative"><entity charOffset="89:99" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="the anticoagulant activity of dabigatran." preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="22:31" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1" text="vitamin k" type="Biomedical_Entity"><Normalization><mmtx cui="C0042878" phraseText="vitamin K" preferredWord="Vitamin K" semType="phsu, lipd, vita"/><RxNorm RxCui="604318"/></Normalization></entity><entity charOffset="63:76" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2" text="anticoagulant" type="Biomedical_Entity"><Normalization><mmtx cui="C3536711" phraseText="the anticoagulant activity of dabigatran." preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="0:17" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3" text="protamine sulfate" type="Biomedical_Entity"><Normalization><mmtx cui="C0033602" phraseText="Protamine sulfate" preferredWord="Protamine Sulfate (USP)" semType="phsu, irda, aapp"/><RxNorm RxCui="236471"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.22.e.2"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23" text="Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs have been used." type="negative"><entity charOffset="107:125" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.0" text="antiplatelet drugs" type="Biomedical_Entity"><Normalization><mmtx cui="C0085826" phraseText="long-acting antiplatelet drugs" preferredWord="Antiplatelet Agents" semType="phsu"/><RxNorm RxCui="42539"/></Normalization></entity><entity charOffset="27:48" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.1" text="platelet concentrates" type="Biomedical_Entity"><Normalization><mmtx cui="C2362067" phraseText="administration of platelet concentrates" preferredWord="Platelet concentrate" semType="phsu"/><RxNorm RxCui="42402"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.23.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25" text="The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose adjusted warfarin or 150, 220, or 300 mg of PRADAXA twice a day. " type="negative"><entity charOffset="121:126" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0" text="align" type="Biomedical_Entity"><Normalization><mmtx cui="C2369992" phraseText="RE-ALIGN" preferredWord="Align" semType="phsu"/><RxNorm RxCui="827148"/></Normalization></entity><entity charOffset="347:354" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.1" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="300 mg of PRADAXA twice" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="312:320" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="27:34" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.3" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="efficacy of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.25.e.2"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26" text="RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm. " type="negative"><entity charOffset="360:368" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="compared to the warfarin treatment arm." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="319:326" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.1" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="in the PRADAXA treatment arm" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="3:8" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.2" text="align" type="Biomedical_Entity"><Normalization><mmtx cui="C2369992" phraseText="RE-ALIGN" preferredWord="Align" semType="phsu"/><RxNorm RxCui="827148"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.26.e.1"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30" text="5.4 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure" type="negative"><entity charOffset="46:56" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.0" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="Inhibitors on Dabigatran Exposure" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="2:18" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.1" text="4 gp" type="Biomedical_Entity"><Normalization><mmtx cui="C0061833" phraseText="5.4 Effect of P-gp Inducers" preferredWord="GP-4 lab number" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.30.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31" lineNumber="35" text="The concomitant use of PRADAXA with P-gp inducers (e.g. rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)]." type="regular"><anaphoraRelation><anaphoraEntity charOffset="86:96" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.6" text="dabigatran" type="Drug"/><antecedentEntity charOffset="23-30" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.0" text="PRADAXA" type="Drug"/></anaphoraRelation><entity charOffset="23:30" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.0" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="The concomitant use of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="36:49" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1" text="P-gp inducers" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="56:64" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.2" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="e.g. rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="66:82" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.4" text="reduces exposure" type="Decrease_Interaction"/><entity charOffset="86:96" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.6" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="exposure to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugClassMembership drug="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.2" drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.4"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.6" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.31.e.4" type="Decrease_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33" lineNumber="37" text="Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone." type="regular"><entity charOffset="19:34" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.0" text="P-gp inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="38:68" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.1" text="patients with renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="92:110" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.2" text="increased exposure" type="Increase_Interaction"/><entity charOffset="114:124" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.4" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="increased exposure of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.1" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.4" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.33.e.2" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34" lineNumber="39" text="Consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA in patients with moderate renal impairment (CrCl 30-50 mL/min). " type="regular"><anaphoraRelation><anaphoraEntity charOffset="124:131" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5" text="PRADAXA" type="Drug"/><antecedentEntity charOffset="30-37" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.2" text="PRADAXA" type="Drug"/></anaphoraRelation><entity charOffset="9:26" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.0" text="reducing the dose" type="Caution_Interaction"/><entity charOffset="30:37" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.2" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="the dose of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="64:75" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="dronedarone" preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="79:100" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4" text="systemic ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="systemic ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="691707"/></Normalization></entity><entity charOffset="124:131" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="coadministered with PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="135:174" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.6" text="patients with moderate renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with moderate renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with moderate renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.6"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.6" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.0" type="Caution_Interaction"/><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.6" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.5" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.34.e.4"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35" lineNumber="39" text="Avoid use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7) and Use in Specific Populations (8.6)]." type="regular"><entity charOffset="0:5" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="0:5" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.2" text="Avoid" type="SPAN"/><entity charOffset="13:20" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.3" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="use of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="25:40" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.4" text="P-gp inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="58:81" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.5" text="severe renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with severe renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with severe renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.4"/></relation><relation type="hasSeverity"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.2"/></relation><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.5"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.3"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.5" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.4" severity="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.2" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.35.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37" lineNumber="43" text="The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)]." type="regular"><anaphoraRelation><anaphoraEntity charOffset="87:97" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.6" text="dabigatran" type="Drug"/><antecedentEntity charOffset="23-30" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.0" text="PRADAXA" type="Drug"/></anaphoraRelation><entity charOffset="23:30" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.0" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="The concomitant use of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="36:49" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1" text="P-gp inducers" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="57:65" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.2" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="67:83" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.4" text="reduces exposure" type="Decrease_Interaction"/><entity charOffset="87:97" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.6" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="exposure to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugClassMembership drug="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.2" drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.6"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.6" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.37.e.4" type="Decrease_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39" lineNumber="45" text="Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone." type="regular"><entity charOffset="19:34" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.0" text="P-gp inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="38:68" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.1" text="patients with renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="92:110" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.2" text="increased exposure" type="Increase_Interaction"/><entity charOffset="114:124" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.4" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="increased exposure of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.2"><relations><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.1" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.4" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.39.e.2" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40" lineNumber="47" text="In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitor dronedarone or systemic ketoconazole. " type="regular"><entity charOffset="73:90" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.0" text="reducing the dose" type="Caution_Interaction"/><entity charOffset="3:42" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.2" text="patients with moderate renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with moderate renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with moderate renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="94:101" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="the dose of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="164:178" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.4" text="P-gp inhibitor" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="179:190" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="concomitantly with the P-gp inhibitor dronedarone" preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="194:215" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7" text="systemic ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="systemic ketoconazole." preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="691707"/></Normalization></entity><drugClassMembership drug="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5" drugClass="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.4"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.2" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.0" type="Caution_Interaction"/><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.2" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.40.e.7"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41" text="The use of P-gp inhibitors (verapamil, amiodarone, quinidine, and clarithromycin) does not require a dose adjustment of PRADAXA. " type="negative"><entity charOffset="66:80" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin" preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="39:49" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1" text="amiodarone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002598" phraseText="amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><entity charOffset="28:37" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2" text="verapamil" type="Biomedical_Entity"><Normalization><mmtx cui="C0042523" phraseText="(verapamil," preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="120:127" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="a dose adjustment of PRADAXA." preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="51:60" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4" text="quinidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034414" phraseText="quinidine," preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.41.e.3"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43" lineNumber="49" text="The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided [see Warnings and Precautions (5.4), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="23:30" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.0" text="PRADAXA" type="Drug"><Normalization><mmtx cui="C2940579" phraseText="The concomitant use of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><entity charOffset="35:50" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.1" text="P-gp inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="71576"/></Normalization></entity><entity charOffset="54:91" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.2" text="patients with severe renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with severe renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with severe renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><entity charOffset="122:129" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.3" text="avoided" type="Caution_Interaction"/><entity charOffset="122:129" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.5" text="avoided" type="SPAN"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.2"/></relation><relation type="hasSeverity"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.5"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.2" ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.1" severity="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.5" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.43.e.3" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46" lineNumber="55" text="Rifampin: Rifampin 600 mg once daily for 7 days followed by a single dose of dabigatran decreased its AUC and Cmax by 66% and 67%, respectively. " type="regular"><entity charOffset="10:18" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.0" text="Rifampin" type="Drug"><Normalization><mmtx cui="C1104996" phraseText="Rifampin 600 mg" preferredWord="Rifampin 600 MG" semType="clnd"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="77:87" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.1" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="followed by a single dose of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="88:97|102:105|110:114" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.2" text="decreased AUC Cmax" type="Decrease_Interaction"/><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.1" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.46.e.2" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47" text="By Day 7 after cessation of rifampin treatment, dabigatran exposure was close to normal [see Warnings and Precautions (5.4) and Drug Interactions (7)]." type="negative"><entity charOffset="28:36" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.0" text="rifampin" type="Biomedical_Entity"><Normalization><mmtx cui="C0035608" phraseText="of rifampin treatment," preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="48:58" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.1" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="dabigatran exposure" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.47.e.1"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49" text="In studies with the P-gp inhibitors ketoconazole, amiodarone, verapamil, and quinidine, the time to peak, terminal half-life, and mean residence time of dabigatran were not affected. " type="negative"><entity charOffset="36:48" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0" text="ketoconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0022625" phraseText="with the P-gp inhibitors ketoconazole," preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="50:60" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1" text="amiodarone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002598" phraseText="amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><entity charOffset="77:86" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2" text="quinidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034414" phraseText="quinidine," preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="62:71" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3" text="verapamil" type="Biomedical_Entity"><Normalization><mmtx cui="C0042523" phraseText="verapamil," preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="153:163" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="mean residence time of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.49.e.4"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51" lineNumber="61" text="Dronedarone: Simultaneous administration of dabigatran etexilate and dronedarone (administered once or twice daily) increases exposure to dabigatran by 70 to 140% compared to dabigatran alone. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="138:148" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.4" text="dabigatran" type="Drug"/><antecedentEntity charOffset="44-64" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.0" text="dabigatran etexilate" type="Drug"/></anaphoraRelation><entity charOffset="44:64" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.0" text="dabigatran etexilate" type="Drug"><Normalization><mmtx cui="C1571583" phraseText="Simultaneous administration of dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="69:80" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.1" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="dronedarone" preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="116:134" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.2" text="increases exposure" type="Increase_Interaction"/><entity charOffset="138:148" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.4" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="exposure to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.4" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.51.e.2" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52" lineNumber="61" text="The increase in exposure is only 30 to 60% higher compared to dabigatran alone when dronedarone is administered 2 hours after dabigatran etexilate." type="regular"><entity charOffset="4:24" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.0" text="increase in exposure" type="Increase_Interaction"/><entity charOffset="84:95" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.2" text="dronedarone" type="Drug"><Normalization><mmtx cui="C0766326" phraseText="dronedarone" preferredWord="dronedarone" semType="phsu, orch"/><RxNorm RxCui="233698"/></Normalization></entity><entity charOffset="126:146" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.3" text="dabigatran etexilate" type="Drug"><Normalization><mmtx cui="C1571583" phraseText="2 hours after dabigatran etexilate." preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.3" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.52.e.0" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53" lineNumber="63" text="Ketoconazole: Systemic ketoconazole increased dabigatran AUC and Cmax values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg." type="regular"><entity charOffset="36:45|57:60|65:69" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.0" text="increased AUC Cmax" type="Increase_Interaction"/><entity charOffset="46:56" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.2" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="dabigatran AUC" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="14:35" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.3" text="Systemic ketoconazole" type="Drug"><Normalization><mmtx cui="C0022625" phraseText="Systemic ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="691707"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.2" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.53.e.0" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54" lineNumber="65" text="Verapamil: When dabigatran etexilate was coadministered with oral verapamil, the Cmax and AUC of dabigatran were increased. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="97:107" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.2" text="dabigatran" type="Drug"/><antecedentEntity charOffset="16-36" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.3" text="dabigatran etexilate" type="Drug"/></anaphoraRelation><entity charOffset="81:85|90:93|113:122" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.0" text="Cmax AUC increased" type="Increase_Interaction"/><entity charOffset="97:107" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.2" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="AUC of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="16:36" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.3" text="dabigatran etexilate" type="Drug"><Normalization><mmtx cui="C1571583" phraseText="dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="61:75" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.4" text="oral verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="coadministered with oral verapamil," preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.2" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.54.e.0" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="5" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56" lineNumber="65" text="If verapamil is present in the gut when dabigatran is taken, it will increase exposure to dabigatran with the greatest increase observed when a single dose of immediate-release verapamil is given one hour prior to dabigatran (AUC increased by a factor of 2.4). " type="regular"><anaphoraRelation><anaphoraEntity charOffset="61:63" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.2" text="it" type="Expression"/><antecedentEntity charOffset="3-12" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.3" text="verapamil" type="Drug"/></anaphoraRelation><anaphoraRelation><anaphoraEntity charOffset="90:100" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.5" text="dabigatran" type="Drug"/><antecedentEntity charOffset="40-50" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.4" text="dabigatran" type="Drug"/></anaphoraRelation><entity charOffset="69:86" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.0" text="increase exposure" type="Increase_Interaction"/><entity charOffset="3:12" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.3" text="verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="verapamil" preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="40:50" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.4" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="90:100" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.5" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="exposure to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="226:239" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.8" text="AUC increased" type="Increase_Interaction"/><entity charOffset="177:186" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.10" text="verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="a single dose of immediate-release verapamil" preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="214:224" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.11" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="one hour prior to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.2"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.ddi.2"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.8"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.11"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.10"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.5" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.0" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.10" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.11" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.56.e.8" type="Increase_Interaction"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57" text="If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible. " type="negative"><entity charOffset="36:46" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.0" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="2 hours after dabigatran," preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="3:12" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.1" text="verapamil" type="Biomedical_Entity"><Normalization><mmtx cui="C0042523" phraseText="verapamil" preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.57.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58" text="In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received verapamil." type="negative"><entity charOffset="141:150" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.0" text="verapamil" type="Biomedical_Entity"><Normalization><mmtx cui="C0042523" phraseText="verapamil." preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="77:87" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.1" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="no important changes in dabigatran trough levels" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.58.e.0"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59" lineNumber="67" text="Amiodarone: When dabigatran etexilate was coadministered with a single 600 mg oral dose of amiodarone, the dabigatran AUC and Cmax increased by 58% and 50%, respectively. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="107:117" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.4" text="dabigatran" type="Drug"/><antecedentEntity charOffset="17-37" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.2" text="dabigatran etexilate" type="Drug"/></anaphoraRelation><entity charOffset="118:121|126:130|131:140" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.0" text="AUC Cmax increased" type="Increase_Interaction"/><entity charOffset="17:37" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.2" text="dabigatran etexilate" type="Drug"><Normalization><mmtx cui="C1571583" phraseText="dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="78:82|91:101" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.3" text="oral amiodarone" type="Drug"><Normalization><mmtx cui="C0002598" phraseText="coadministered with a single 600 mg oral dose of amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="107:117" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.4" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="the dabigatran AUC" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.4" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.59.e.0" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60" lineNumber="67" text="The increase in exposure was mitigated by a 65% increase in the renal clearance of dabigatran in the presence of amiodarone. " type="regular"><entity charOffset="48:79" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.0" text="increase in the renal clearance" type="Decrease_Interaction"/><entity charOffset="83:93" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.2" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="of dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="113:123" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.3" text="amiodarone" type="Drug"><Normalization><mmtx cui="C0002598" phraseText="of amiodarone." preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.0"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.3" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.60.e.0" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62" text="In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone." type="negative"><entity charOffset="77:87" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.0" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="no important changes in dabigatran trough levels" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="141:151" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.1" text="amiodarone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002598" phraseText="amiodarone." preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.62.e.1"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64" text="Dabigatran etexilate was given over 3 consecutive days, the last evening dose on Day 3 with or without quinidine pre-dosing. " type="negative"><entity charOffset="0:20" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.0" text="dabigatran etexilate" type="Biomedical_Entity"><Normalization><mmtx cui="C1571583" phraseText="Dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="103:112" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.1" text="quinidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034414" phraseText="or without quinidine pre-dosing." preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.64.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65" lineNumber="69" text="Concomitant quinidine administration increased dabigatran s AUC and Cmax by 53% and 56%, respectively." type="regular"><entity charOffset="12:21" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.0" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="Concomitant quinidine administration" preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="37:46|60:63|68:72" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.1" text="increased AUC Cmax" type="Increase_Interaction"/><entity charOffset="47:57" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.3" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="dabigatran s AUC" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.1"><relations><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.3" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.65.e.1" type="Increase_Interaction"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66" text="Clarithromycin: Coadministered clarithromycin had no impact on the exposure to dabigatran." type="negative"><entity charOffset="0:14" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.0" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="Clarithromycin" preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="31:45" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.1" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="Coadministered clarithromycin" preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="79:89" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.2" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="to dabigatran." preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.66.e.2"/></sentence><sentence biomedicalEntities="3" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68" lineNumber="75" text="Clopidogrel: When dabigatran etexilate was given concomitantly with a loading dose of 300 mg or 600 mg clopidogrel, the dabigatran AUC and Cmax increased by approximately 30% and 40%, respectively. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="120:130" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.2" text="dabigatran" type="Drug"/><antecedentEntity charOffset="18-38" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.3" text="dabigatran etexilate" type="Drug"/></anaphoraRelation><entity charOffset="131:134|139:143|144:153" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.0" text="AUC Cmax increased" type="Increase_Interaction"/><entity charOffset="120:130" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.2" text="dabigatran" type="Drug"><Normalization><mmtx cui="C2348066" phraseText="the dabigatran AUC" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="18:38" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.3" text="dabigatran etexilate" type="Drug"><Normalization><mmtx cui="C1571583" phraseText="dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="103:114" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.4" text="clopidogrel" type="Drug"><Normalization><mmtx cui="C0070166" phraseText="600 mg clopidogrel," preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><drugInteraction id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.ddi.1"><interaction trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.2" trigger="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.68.e.0" type="Increase_Interaction"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69" text="The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. " type="negative"><entity charOffset="147:158" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.0" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="compared to clopidogrel monotherapy." preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="59:70" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.1" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel" preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="34:54" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.2" text="dabigatran etexilate" type="Biomedical_Entity"><Normalization><mmtx cui="C1571583" phraseText="The concomitant administration of dabigatran etexilate" preferredWord="dabigatran etexilate" semType="phsu, orch"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.69.e.1"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70" text="When comparing combined treatment and the respective mono-treatments, the coagulation measures for dabigatran s effect (aPTT, ECT, and TT) remained unchanged, and inhibition of platelet aggregation (IPA), a measurement of clopidogrel s effect, remained unchanged." type="negative"><entity charOffset="222:233" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.0" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="a measurement of clopidogrel s effect," preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="99:109" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.1" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="measures for dabigatran s effect" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.70.e.0"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71" text="Enoxaparin: Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT." type="negative"><entity charOffset="12:22" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.0" text="enoxaparin" type="Biomedical_Entity"><Normalization><mmtx cui="C0206460" phraseText="Enoxaparin 40 mg" preferredWord="Enoxaparin" semType="phsu, carb"/><RxNorm RxCui="67108"/></Normalization></entity><entity charOffset="160:170" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="to dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.2" text="enoxaparin" type="Biomedical_Entity"><Normalization><mmtx cui="C0206460" phraseText="Enoxaparin" preferredWord="Enoxaparin" semType="phsu, carb"/><RxNorm RxCui="67108"/></Normalization></entity><entity charOffset="119:126" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3" text="pradaxa" type="Biomedical_Entity"><Normalization><mmtx cui="C2940579" phraseText="24 hours before a single dose of PRADAXA" preferredWord="Pradaxa" semType="phsu"/><RxNorm RxCui="1037046"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.1"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.71.e.3"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72" text="Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran." type="negative"><entity charOffset="12:22" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0" text="ranitidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034665" phraseText="Ranitidine," preferredWord="Ranitidine" semType="phsu, orch"/><RxNorm RxCui="203136"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1" text="diclofenac" type="Biomedical_Entity"><Normalization><mmtx cui="C0012091" phraseText="Diclofenac," preferredWord="Diclofenac" semType="phsu, orch"/><RxNorm RxCui="3355"/></Normalization></entity><entity charOffset="76:86" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="exposure to dabigatran." preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="28:35" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="Digoxin" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.72.e.2"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74" text="The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran." type="negative"><entity charOffset="67:74" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="digoxin" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="23:45" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1" text="proton pump inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0358591" phraseText="The concomitant use of proton pump inhibitors," preferredWord="Proton Pump Inhibitors" semType="phsu"/><RxNorm RxCui="8879"/></Normalization></entity><entity charOffset="47:61" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2" text="h2 antagonists" type="Biomedical_Entity"><Normalization><mmtx cui="C0019593" phraseText="H2 antagonists," preferredWord="Histamine H2 Antagonists" semType="phsu"/><RxNorm RxCui="34748"/></Normalization></entity><entity charOffset="130:140" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="the trough concentration of dabigatran." preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.74.e.3"/></sentence><sentence id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76" text="In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine." type="negative"><entity charOffset="209:221" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0" text="pantoprazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0081876" phraseText="pantoprazole," preferredWord="pantoprazole" semType="phsu, orch"/><RxNorm RxCui="40790"/></Normalization></entity><entity charOffset="71:81" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" text="dabigatran" type="Biomedical_Entity"><Normalization><mmtx cui="C2348066" phraseText="dabigatran" preferredWord="dabigatran" semType="phsu"/><RxNorm RxCui="814696"/></Normalization></entity><entity charOffset="159:173" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" text="clarithromycin" type="Biomedical_Entity"><Normalization><mmtx cui="C0055856" phraseText="clarithromycin," preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="187:198" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3" text="clopidogrel" type="Biomedical_Entity"><Normalization><mmtx cui="C0070166" phraseText="clopidogrel," preferredWord="clopidogrel" semType="phsu, orch"/><RxNorm RxCui="236991"/></Normalization></entity><entity charOffset="200:207" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="digoxin," preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="145:157" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" text="atorvastatin" type="Biomedical_Entity"><Normalization><mmtx cui="C0286651" phraseText="atorvastatin," preferredWord="atorvastatin" semType="phsu, orch"/><RxNorm RxCui="83367"/></Normalization></entity><entity charOffset="226:236" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6" text="ranitidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034665" phraseText="ranitidine." preferredWord="Ranitidine" semType="phsu, orch"/><RxNorm RxCui="203136"/></Normalization></entity><entity charOffset="175:185" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7" text="diclofenac" type="Biomedical_Entity"><Normalization><mmtx cui="C0012091" phraseText="diclofenac," preferredWord="Diclofenac" semType="phsu, orch"/><RxNorm RxCui="3355"/></Normalization></entity><entity charOffset="133:143" id="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" text="amiodarone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002598" phraseText="the pharmacokinetics of amiodarone," preferredWord="Amiodarone" semType="phsu, orch"/><RxNorm RxCui="203114"/></Normalization></entity><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.0"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.1" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.2"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.3"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.4"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.5"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.6"/><pair ddi="false" e1="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.8" e2="Dailymed.ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.s.76.e.7"/></sentence><positiveExamples number="22"/><negativeExamples number="115"/></document>